Ryosuke Matsukane

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Community Dwelling

Top Venues

Scientific reports

International journal of clinical oncology

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Ryosuke Matsukane, Takahiro Oyama, Ryosuke Tatsuta, Sakiko Kimura, Kojiro Hata, Shuhei Urata, Hiroyuki Watanabe
Real-World Prevalence and Tolerability of Immune-Related Adverse Events in Older Adults with Non-Small Cell Lung Cancer: A Multi-Institutional Retrospective Study. Cancers 16 (11) (2024)
Ryosuke Matsukane, Takahiro Oyama, Ryosuke Tatsuta, Sakiko Kimura, Kojiro Hata, Shuhei Urata, Hiroyuki Watanabe
Real-World Prevalence and Tolerability of Immune-Related Adverse Events in Older Adults with Non-Small Cell Lung Cancer: A Multi-Institutional Retrospective Study. Cancers 16 (11) (2024)
Ryosuke Matsukane, Kimitaka Suetsugu, Kojiro Hata, Keisuke Matsuda, Satoshi Nakao, Haruna Minami, Hiroyuki Watanabe, Takeshi Hirota, Nobuaki Egashira, Hiroshi Araki
Systematic surveillance of immune-related adverse events in clinical practice and impact of subsequent steroid medication on survival outcomes. International journal of clinical oncology (2023)
Tsukasa Shimauchi, Takuro Numaga-Tomita, Yuri Kato, Hiroyuki Morimoto, Kosuke Sakata, Ryosuke Matsukane, Akiyuki Nishimura, Kazuhiro Nishiyama, Atsushi Shibuta, Yutoku Horiuchi, Hitoshi Kurose, Sang Geon Kim, Yasuteru Urano, Takashi Ohshima, Motohiro Nishida
A TRPC3/6 Channel Inhibitor Promotes Arteriogenesis after Hind-Limb Ischemia. Cells 11 (13) (2022)
Ryosuke Matsukane, Kimitaka Suetsugu, Takeshi Hirota, Hiroshi Araki
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406. Clinical pharmacokinetics 61 (7) (2022)
Ryosuke Matsukane, Hiroyuki Watanabe, Kojiro Hata, Kimitaka Suetsugu, Toshikazu Tsuji, Nobuaki Egashira, Yoichi Nakanishi, Isamu Okamoto, Hiroshi Araki
Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. Scientific reports 11 (1) (2021)